| Mr Gregory J Pryor, LCSW, LCADC | |
|
401 North Route 73, Building 10, Suite 110, Marlton, NJ 08053 | |
| (609) 280-6998 | |
| (856) 983-1511 |
| Full Name | Mr Gregory J Pryor |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 401 North Route 73, Marlton, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124293428 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | 37LC00025400 (New Jersey) | Secondary |
| 1041C0700X | Social Worker - Clinical | 44SC05265600 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Gregory J Pryor, LCSW, LCADC 302a Barton Run Blvd, Marlton, NJ 08053 Ph: (609) 280-6998 | Mr Gregory J Pryor, LCSW, LCADC 401 North Route 73, Building 10, Suite 110, Marlton, NJ 08053 Ph: (609) 280-6998 |
News Archive
Medasys Inc., a medical device company focused on providing implantable drug delivery solutions, announced today that it has received PMA approval from the U. S. Food and Drug Administration for its Prometra programmable implantable drug pump.
Researchers at the University of Granada have designed a set of biomarkers that can be used in diagnostic tests for the detection of dengue and the West Nile virus, two infectious diseases transmitted by the bite of a mosquito. These biomarkers can be used to identify these viral diseases, which affect millions of people worldwide.
A public inquiry into conditions and care at Stafford hospital in Stafford, England heard that the hospital was violating basic human rights of the patients. The counsel for Cure the NHS, a campaign group set up by relatives of some of the people who died at the hospital after receiving inadequate treatment established the fact that the standard of care constituted inhuman and degrading treatment at the facility.
Small, non-coding molecules called microRNAs are known to play an important role in cancer development. Researchers now have shown their significance is greater than previously thought, a finding that could lead to new therapeutic approaches for the most common and deadly form of ovarian cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.
› Verified 3 days ago